Skip to content
Search
Please enter at least 3 characters.

Latest Stories

Pharmacy technician shaves off her blue locks to support cancer charity

Pharmacy technician shaves off her blue locks to support cancer charity

Sam Smith braves the shave to raise funds for Macmillan Cancer Support and cancer patients at North Tees and Hartlepool NHS Foundation Trust

A Middlesbrough pharmacy worker has raised nearly £1,000 for cancer support by participating in 'Brave the Shave,' a charity fundraising campaign organised in memory of some of her colleagues who lost their battle with cancer.

Sam Smith, a trainee pharmacy technician at the University Hospital of North Tees shaved off her blue hair to support two cancer services: the cancer information centre at her hospital and Macmillan Cancer Support.


The 34-year-old's brave decision began this summer after she commented about shaving her head to cope with the heat. A colleague jokingly offered her £5 to follow through, which sparked the idea to turn the gesture into a charity fundraiser - Brave the Shave.

In a video shared by the University, Sam is seen getting her head shaved at the hospital while her pharmacy colleagues cheer her on.

Teesside pharmacy worker raises nearly £1,000 for cancer support by shaving off her blue locks

Sporting a bald head, Sam said: "It doesn't feel like my head right now but it's very liberating.

"I said I wouldn't do it for anything less than £300 so to raise just shy of £1,000 is amazing. Thank you to everybody who has donated – you've made it all worth it.”

Sam shared that their department has lost some colleagues to cancer over the past few years, including a friend this year, which had a big impact on the pharmacy team.

"Most people at some point will be or have been affected by cancer. If we can do something to help support people or make things easier even in a small way, then why not? It's only hair,” she added.

Sam with her colleagues at the University Hospital of North Tees Sam with her colleagues (Photo credit: North Tees and Hartlepool NHS Foundation Trust at the University Hospital of North Tees)

The funds raised by Sam will be split between the hospital's cancer information centre and Macmillan Cancer Support.

The donation to the hospital’s cancer information centre will go toward purchasing headwear for cancer patients under the care of North Tees and Hartlepool NHS Foundation Trust. The centre offers a confidential walk-in service for anyone with questions or concerns about cancer.

To support Sam’s cause, you can donate to her fundraiser for the cancer information centre at North Tees and Hartlepool NHS Foundation Trust by visiting here, or contribute to her fundraiser for Macmillan Cancer Support by visiting here.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less